Abstract
BackgroundGolimumab (GOL) has shown its efficacy and safety in various randomized clinical trials with patients eligible for clinical studies. Data from daily clinical practice in Germany are still lacking.ObjectivesTo gather...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have